NCT07758621尚未招募3 期
A Randomized, Controlled, Open-Label, Multicenter Phase 3 Trial Evaluating the Efficacy and Safety of SYS6010 Versus Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
CSPC Megalith Biopharmaceutical Co.,Ltd.0 个研究点目标入组 340 人开始时间: 2026年8月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 340
- 主要终点
- Objective Response Rate (ORR) as assessed by IRC per RECIST v.1.1.
研究概览
简要总结
This study is a randomized, controlled, open-label, multicenter phase III clinical trial, which aims to evaluate the efficacy, safety of SYS6010 compared with monotherapy in participants with HNSCC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participantss aged 18-75 years (inclusive);
- •Patients with pathologically confirmed head and neck squamous cell carcinoma (HNSCC);.
- •Participants have failed of platinum-based chemotherapy and PD-(L)1 inhibitors; for participants who received platinum-based chemotherapy and PD-(L)1 inhibitors in the adjuvant/neoadjuvant setting, disease recurrence or progression must have occurred within 6 months after completion of that therapy; radiographically confirmed disease progression during or after the most recent treatment regimen;
- •Participants must have measurable disease according to RECIST (version 1.1);
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- •Life expectancy of ≥ 3 months;
- •Adequate major organ function (hematology, renal, liver, and coagulation) as determined by laboratory tests performed within 7 days prior to randomization;
- •Sexually active fertile participants must agree to use methods of contraception during the study and at least 7 months after termination of study therapy and have a negative serum pregnancy test within 7 days prior to randomization;
- •Willing to participate in the study, understand the study procedures, and sign a written informed consent form.
排除标准
- •Pathologically confirmed patients with adenocarcinoma or sarcomatoid carcinoma etc.;
- •Active central nervous system metastases or leptomeningeal metastasis;
- •History of another malignancy within 3 years prior to randomization
- •Allergy to any component of SYS6010 or to humanized monoclonal antibodies，or to the control drugs (docetaxel, methotrexate, paclitaxel, cetuximab);
- •Prior treatment with TOP1(including ADCs);
- •Prior EGFR mAb therapy within 4 months prior to treatment;
- •Adverse events from prior antitumor therapy not recovered to Grade ≤ 1 per NCI-CTCAE v6.0；
- •Use of any of the medications or treatments within the specified washout period (prior to randomization )
- •History of serious cardiovascular or cerebrovascular conditions within 6 months prior to randomization, including but not limited to: Severe arrhythmias (e.g., ventricular arrhythmias requiring clinical intervention, third-degree atrioventricular block, QTcF > 470 ms) (Fridericia formula: QTcF = QT/RR0.33, RR = 60/heart rate). Myocardial infarction, unstable angina, aortic dissection, angioplasty, or coronary artery bypass surgery. NYHA class II or higher heart failure with LVEF < 50%.Stroke or other grade ≥ 3 cardiovascular/cerebrovascular events. pulmonary embolism;
- •Imaging examination suggests tumor invasion of the cervical, thoracic, and abdominal great vessels; and the investigator assessed that there was no risk of bleeding.
- •Patients who have a history of ILD/non-infectious pneumonitis treated with corticosteroids in the past, currently have ILD/non-infectious pneumonitis, for whom imaging examinations at screening cannot rule out ILD/non-infectious pneumonitis,
- •Severe infection within 4 weeks prior to randomization, such as bacteremia requiring hospitalization, severe pneumonia, or active pulmonary tuberculosis;active systemic infections requiring antibiotics within 2 weeks prior to randomization;
- •Previous permanent discontinuation of EGFR-targeted therapy due to skin toxicity, or currently have skin diseases requiring oral or intravenous medication;
- •History of ulcerative colitis or Crohn's disease;
- •Pleural effusion or pericardial effusion requiring clinical intervention within 2 weeks prior to randomization;
- •Active HBV or HCV infection (hepatitis B surface antigen and/or hepatitis B core antibody positive and HBV DNA copies ≥ 1×10^4 copies/mL or ≥ 2000 IU/mL, HCV antibody positive and HCV RNA above the lower limit of detection of the analytical procedure). Note: For HBsAg-positive patients, it is recommended to start antiviral therapy before randomization, nucleoside analogues are recommended, such as entecavir, tenofovir disoproxil;
- •History of immunodeficiency (including positive HIV test, other acquired or congenital immunodeficiency diseases), history of allogeneic stem cell or organ transplant;
- •Other conditions that the investigator deems unsuitable for participation in this clinical study (such as mental disorders, macular cystoid oedema, severe corneal disorders, uncontrolled or poorly controlled hypertension and diabetes mellitus, impaired oxygenation requiring continuous oxygen supplementation, etc.).
研究组 & 干预措施
SYS6010
Experimental
SYS6010 monotherapy
干预措施: SYS6010 (Drug)
Investigator's choice of monotherapy
Active Comparator
Investigator's choice of one of treatment (docetaxel,methotrexate, paclitaxel or cetuximab)
干预措施: Investigator's Choice of monotherapy (Drug)
结局指标
主要结局
Objective Response Rate (ORR) as assessed by IRC per RECIST v.1.1.
时间窗: Up to approximately 2 years
Objective response rate is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per RECIST v.1.1.
Overall Survival
时间窗: Up to approximately 2 years
Overall survival is defined as the time from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time will be censored at the last date the participant is known to be alive.
次要结局
- Plasma concentrations of total antibodies(Up to approximately 2 years)
- Objective Response Rate (ORR) as assessed by investigators(Up to approximately 2 years)
- Duration of Response (DOR)(Up to approximately 2 years)
- Disease Control Rate (DCR)(Up to approximately 2 years)
- Progression Free Survival (PFS)(Up to approximately 2 years)
- Incidence of adverse events assessed by CTCAE v6.0.(Up to approximately 2 years)
- Incidence of Anti-Drug Antibody (ADA)(Up to approximately 2 years)
- Plasma concentrations of toxin-bound antibodies(Up to approximately 2 years)
研究者
相似试验
尚未招募
3 期
SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial CarcinomaUrothelial CarcinomaNCT07526792CSPC Megalith Biopharmaceutical Co.,Ltd.406
招募中
3 期
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate CancerPSMA-Positive Progressive Metastatic Castration-Resistant Prostate CancerNCT07311694Jiangsu HengRui Medicine Co., Ltd.370
招募中
3 期
JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction AdenocarcinomaGastric AdenocarcinomaNCT07584135NingBo Junyan Hongshi Biosciences Co., Ltd600
尚未招募
2 期
SYS6002 vs PADCEV in Patients With Advanced Urothelial CarcinomaAdvanced Urothelial CarcinomaNCT07374549CSPC Megalith Biopharmaceutical Co.,Ltd.100
尚未招募
3 期
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerResectable HER2-positive Breast CancerNCT07441460Shanghai JMT-Bio Inc.1,800